Xeronaks 2.5

---

(Tirzepatide Injection, 2.5 mg / 0.5 ml)

Each pre-filled syringe contains 2.5 mg Tirzepatide INN in 0.5 ml solution for injection.

Solution for Injection. Prefilled Syringe

Xeronaks 2.5 Injection is indicated:
1. For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.
2. For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of
• ≥ 30 kg/ m2 (obesity) or
• ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
For study results with respect to combinations, effects on glycaemic control, weight reduction and the populations studied.